Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2005-06-07
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S277000, C514S315000, C514S318000, C514S333000, C514S336000, C514S340000, C514S364000, C514S247000, C514S383000, C546S184000, C546S193000, C546S210000, C546S223000, C546S236000, C546S269100, C548S125000, C548S131000
Reexamination Certificate
active
06903085
ABSTRACT:
The invention provides compounds of formula (I) wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions
REFERENCES:
patent: 3203992 (1965-08-01), Kunz et al.
patent: 3577432 (1971-05-01), Helsley et al.
patent: 3755584 (1973-08-01), Plotnikoff et al.
patent: 3818017 (1974-06-01), Janssen et al.
patent: 3894030 (1975-07-01), Janssen et al.
patent: 4029801 (1977-06-01), Cavalla et al.
patent: 4105666 (1978-08-01), Ward
patent: 4105771 (1978-08-01), Archibald et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4246267 (1981-01-01), Vincent et al.
patent: 4264613 (1981-04-01), Regnier et al.
patent: 4338323 (1982-07-01), Regnier et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5688960 (1997-11-01), Shankar
patent: 5696267 (1997-12-01), Reichard et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 5840725 (1998-11-01), Reichard et al.
patent: 37 23 568 (1989-01-01), None
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 354 568 (1990-02-01), None
patent: 0 407 217 (1991-01-01), None
patent: 0 445 862 (1991-09-01), None
patent: 0 457 686 (1991-11-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 625 507 (1994-11-01), None
patent: 0 643 057 (1995-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-03-01), None
patent: 1013276 (2000-06-01), None
patent: 2 190 430 (1974-02-01), None
patent: 1368012 (1974-09-01), None
patent: 1 404 868 (1975-09-01), None
patent: 1425354 (1976-02-01), None
patent: 1 532 671 (1978-11-01), None
patent: 1 538 542 (1979-01-01), None
patent: 1 544 191 (1979-04-01), None
patent: 63-264525 (1988-11-01), None
patent: 10259176 (1998-06-01), None
patent: 10259176 (1998-09-01), None
patent: WO 92/15579 (1992-09-01), None
patent: 9313083 (1993-07-01), None
patent: WO 93/25528 (1993-12-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 95/11880 (1995-05-01), None
patent: WO 96/26205 (1996-08-01), None
patent: WO 96/34857 (1996-11-01), None
patent: WO 96/39386 (1996-12-01), None
patent: WO 97/10207 (1997-03-01), None
patent: WO 97/19060 (1997-05-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 97/42956 (1997-11-01), None
patent: WO 97/47299 (1997-12-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/08826 (1998-03-01), None
patent: WO 98/31364 (1998-07-01), None
patent: WO 98/31366 (1998-07-01), None
patent: WO 98/32442 (1998-07-01), None
patent: WO 98/51311 (1998-11-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/27928 (1999-06-01), None
patent: WO 99/27929 (1999-06-01), None
patent: WO 99/28314 (1999-06-01), None
patent: WO 99/31092 (1999-06-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 99/37619 (1999-07-01), None
patent: WO 99/38514 (1999-08-01), None
patent: WO 99/64394 (1999-12-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/08013 (2000-02-01), None
patent: WO 00/21948 (2000-04-01), None
patent: WO 00/21952 (2000-04-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/39108 (2000-07-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/58305 (2000-10-01), None
patent: WO 00/61559 (2000-10-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 00/76513 (2000-12-01), None
patent: WO 00/76973 (2000-12-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/43744 (2001-06-01), None
patent: WO 01/44227 (2001-06-01), None
patent: WO 01/92227 (2001-12-01), None
Chemical ASbstract DN 129:310895, also cited as Jp10259176.
Chemical Abstract DN 120:30773, also cited as WO 9313083.
Granata et al, PubMed Abstract 12876405, also cited as Int Arch Allergy Immunol., 131/3, 153-63(2003).
Scott et al,PubMed Abstract 12783578, also cited as Expert Opin Ther. Targets, 7/3,427-40(2003).
Craig Gerard, “Chemokine Receptors and Ligand Specificity: Understanding the Enigma” vol. 13, No. 72 (C-570), 21-31, Feb. 17, 1999.
Patent Abstracts of Japan, Medicine Composition Containing Piperazine Derivative and Having Active Oxygen Production Inhibiting And Active Oxygen Removing Action (Nov. 1, 1988).
Derwent Abstract 2000-587420/55, (2003), corresponding to Foreign Patent Document WO 00/53600, published Sep. 14, 2000 (Reference AT above).
Derwent Abstract 97-212513/19, (2003), corresponding to Foreign Patent Document WO 97/10207 A1, published Mar. 20, 1997 (Reference AQ Above).
Derwent Abstract 98-351249/49, (2003), corresponding to Foreign Patent Document JP 63-264525, published Nov. 1, 1988 (Reference AU above).
J. Hesselgesser et al., Journal of Biological Chemistry, vol. 273, No. 25, “Identification and Characterisation of Small Molecule Funtional Antagonisty of the CCR1 Chemokine Receptor” 15687-15692, (1998).
Howard P. Ng et al., Journal of Medicinal Chemistry, vol. 42, “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists” 4680-4694, (1999).
Xavier Emodns-Alt et al., Bioorganic & Medicinal Chemistry Letters, vol. 3, No. 5, “Pharmacological Profile and Chemical Synthesis of SR 48968, a Non-Peptide Antagonist of the Neurokinin A (NK2) Receptor” 925-930, (1993).
U.S. Appl. No. 10/276,430, Burrows et al., filed Dec. 10, 2002.
U.S. Appl. No. 10/468,179, Broush et al., filed Aug. 18, 2003.
U.S. Appl. No. 10/469,361, Burrows et al., filed Aug. 26, 2003.
U.S. Appl. No. 10/472,350, Burrows et al., filed Sep. 18, 2003.
U.S. Appl. No. 10/473,258, Burrows et al., filed Sep. 29, 2003.
U.S. Appl. No. 10/495,196, Tucker, filed May 11, 2004.
U.S. Appl. No. 10/495,410, Cummins et al., filed May 13, 2004.
U.S. Appl. No. 10/495,405, Cummins et al., May 12, 2004.
Archibald et al., “Antihypertensive Ureidopiperidines”,J. Med. Chem. 23:857-861 (1980).
Archibald et al., “Antiinflammatory 4-acylaminopiperidines”,CAPLUS77:34355 (1972).
CAPLUS accession No. 1978:22640, document No. 88:22640, Yoshitomi Pharmaceutical Industries Ltd.: “Urea and thiourea derivatives” & JO A2, 52085174, 19700715.
CAPLUS, accession No. 1990:558675, document No. 113:158675, Yoshitomi Pharmaceutical Industries, Ltd.: Dihydroxycinnamic acid amide derivatives and their pharmaceutical compositions for enhancement of nerve growth factor (NGF) production & JP, A2, 02104568, 19900417.
Cattanach et al., “Studies in the Indole Series. Part IV, Tetrahydro-1H-pyrido [4,3-b]-indoles as Serotonin Antagonists”,J. Chem. Soc.(C) 10:1235-1243 (1968).
Cohen et al., “Cytokine function: A study in biologic diversity”,CAPLUS125:31527 (1996).
Derwent Abstract 54050W/33 corresponding to Belgium Application BE 826994.
Derwent Abstract 93-339628/29 corresponding to PCT Application WO 00/23437 A1.
Derwent Abstract 96-136185/14 corresponding to Japanese Patent Application JP 08026999.
Derwent Abstract 96-136186/14 corresponding to Japanese Patent Application JP 08027000-A.
Derwent Abstract 96-136187/14 corresponding to Japanese Patent Application JP 08027001-A.
Derwent Abstract 99-040684/04 corresponding to Japanese Patent Application JP 10298180-A/2.
Friebe et al., “Piperidinopropyl dervatives and pharmaceutical compositions containing them ”,CAPLUS94:103172 (1981).
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCRI Chemokine Receptor”,J. Biol. Chem.273(25):15687-15692 (1998).
Howard et al., “Chemokines: progress toward identifying molecular targets for therapeutic a
Baxter Andrew
Evans Richard
Harden David
Kindor Nicholas
Marriott David
AstraZeneca AB
Patel Sudhgaker B.
Raymond Richard L.
LandOfFree
Substituted piperidine compounds useful as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperidine compounds useful as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidine compounds useful as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516753